Deepthi S. Akella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deepthi S. Akella has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Michele Marie Carr
Department of Otolaryngology, Head and Neck Surgery Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo Buffalo New York USA
4 shared publications - Gaayathri Varavenkataraman
Department of Otolaryngology, Head and Neck Surgery Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo Buffalo New York USA
2 shared publications - Abraham A. Kassem
Jacobs School of Medicine and Biomedical Sciences University at Buffalo, Buffalo New York USA
1 shared publication - Alexa F. Ibrahim
Jacobs School of Medicine and Biomedical Sciences University at Buffalo, Buffalo New York USA
1 shared publication Chennai A. Marcus
Department of Foundational Medical Studies Oakland University William Beaumont School of Medicine Rochester Michigan USA
1 shared publication- Chloe Cottone
University at Buffalo Jacobs School of Medicine and Biomedical Sciences, New York, United States
1 shared publication
Latest Publications
- 17 November 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps
Objective: To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design: Retrospective cohort study. Setting: TriNetX United States Collaborative Network. Methods: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. Results: In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. Conclusion: These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.
- 17 November 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps
Objective: To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design: Retrospective cohort study. Setting: TriNetX United States Collaborative Network. Methods: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. Results: In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. Conclusion: These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.
- 31 October 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 174 (1) , 137-142
Clostridioides difficile Infection Risk in Children Prescribed Antibiotics for Tonsillectomy
Objective: To evaluate whether antibiotic use in pediatric patients undergoing tonsillectomy is associated with an increased risk of Clostridioides difficile infection (CDI). Study Design: Retrospective cohort study. Setting: US Network in TriNetX. Methods: Patients younger than 18 years who underwent tonsillectomy between 2006 and 2024 were identified using CPT codes 42820, 42821, 42825, or 42826, SNOMED codes 173422009 or 28913000, or ICD‐10‐PCS code 0CTP. Two cohorts were created based on whether antibiotics were prescribed within 7 days of surgery. Antibiotic use was identified through medication records. Propensity score matching was applied for age, sex, and race. CDI within 90 days was identified using ICD‐10 code A04.7. Results: Between 2006 and 2024, antibiotics were prescribed to 16.5% (N = 58,845/356,950) of children undergoing tonsillectomy. After matching, each cohort included 58,722 patients (mean age 6.7 ± 4.1 years). The most common antibiotic prescribed was amoxicillin (N = 37,217, 63.4%), followed by cefazolin (N = 10,226, 17.4%). The prevalence of CDI was significantly higher in the antibiotic group (N = 42, 0.07%) compared to the nonantibiotic group (N = 10, 0.02%, P < .0001). Antibiotic exposure was associated with a fourfold increased risk of CDI (risk ratio [RR] = 4.2, 95% CI: 2.1‐8.4, P < .001). Conclusion: Despite recommendations against routine antibiotic use in tonsillectomy, a substantial proportion of children receive them. This practice is linked to an elevated risk of CDI, emphasizing the importance of antibiotic stewardship in surgical care.
- 31 October 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 174 (1) , 137-142
Clostridioides difficile Infection Risk in Children Prescribed Antibiotics for Tonsillectomy
Objective: To evaluate whether antibiotic use in pediatric patients undergoing tonsillectomy is associated with an increased risk of Clostridioides difficile infection (CDI). Study Design: Retrospective cohort study. Setting: US Network in TriNetX. Methods: Patients younger than 18 years who underwent tonsillectomy between 2006 and 2024 were identified using CPT codes 42820, 42821, 42825, or 42826, SNOMED codes 173422009 or 28913000, or ICD‐10‐PCS code 0CTP. Two cohorts were created based on whether antibiotics were prescribed within 7 days of surgery. Antibiotic use was identified through medication records. Propensity score matching was applied for age, sex, and race. CDI within 90 days was identified using ICD‐10 code A04.7. Results: Between 2006 and 2024, antibiotics were prescribed to 16.5% (N = 58,845/356,950) of children undergoing tonsillectomy. After matching, each cohort included 58,722 patients (mean age 6.7 ± 4.1 years). The most common antibiotic prescribed was amoxicillin (N = 37,217, 63.4%), followed by cefazolin (N = 10,226, 17.4%). The prevalence of CDI was significantly higher in the antibiotic group (N = 42, 0.07%) compared to the nonantibiotic group (N = 10, 0.02%, P < .0001). Antibiotic exposure was associated with a fourfold increased risk of CDI (risk ratio [RR] = 4.2, 95% CI: 2.1‐8.4, P < .001). Conclusion: Despite recommendations against routine antibiotic use in tonsillectomy, a substantial proportion of children receive them. This practice is linked to an elevated risk of CDI, emphasizing the importance of antibiotic stewardship in surgical care.
- 27 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (6) , 1958-1963
Are More Adults Bleeding After Tonsillectomy Than in the Past?
Objective: Post‐tonsillectomy hemorrhage (PTH) rates have increased in children over the last decade. This study aimed to determine whether PTH incidence in adults had also increased over the last 15 years.Study Design: Retrospective study.Setting: TriNetX database.Methods: A search was conducted using TriNetX for patients 18 years and older within the US Collaborative Network who had undergone tonsillectomy (CPT codes 42821 or 42826) and yielded 72,232 subjects. PTH diagnoses were identified using ICD‐10 codes J95.830 or K91.840, and those who returned to the operating room (RTOR) to control PTH were identified using CPT 42962. PTH events that occurred and analgesics given following 14 days of tonsillectomy were tabulated annually from 2008 to 2022. Mann‐Kendall test for monotonic trend examined significant trends in PTH and analgesic use.Results: Mean age at tonsillectomy was 32.8 years (SD = 13.8). 4.1% were diagnosed with PTH in 2008, compared with 6.2% by 2022 (p = 0.0030). In 2008, 0.7% required RTOR to control PTH, compared with 2.4% in 2022 (p < 0.0001). Use of codeine decreased from 6.9% in 2008 to 2.5% in 2022 (p = 0.0022). Use of ibuprofen, acetaminophen, ketorolac, and oxycodone increased from 1.6% to 23.4% (p = 0.0005), 36.1% to 78.6% (p < 0.0001), 1.5% to 11.9% (p < 0.0001), and 20.6% to 63.6% (p < 0.0001), respectively. No change was detected in use of hydrocodone.Conclusion: Post‐tonsillectomy analgesia in adults has changed significantly over the last 15 years. Our study highlights a concurrent increase in PTH which bears more investigation.Level of Evidence: 3 Laryngoscope, 135:1958–1963, 2025
- 27 January 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (6) , 1958-1963
Are More Adults Bleeding After Tonsillectomy Than in the Past?
Objective: Post‐tonsillectomy hemorrhage (PTH) rates have increased in children over the last decade. This study aimed to determine whether PTH incidence in adults had also increased over the last 15 years.Study Design: Retrospective study.Setting: TriNetX database.Methods: A search was conducted using TriNetX for patients 18 years and older within the US Collaborative Network who had undergone tonsillectomy (CPT codes 42821 or 42826) and yielded 72,232 subjects. PTH diagnoses were identified using ICD‐10 codes J95.830 or K91.840, and those who returned to the operating room (RTOR) to control PTH were identified using CPT 42962. PTH events that occurred and analgesics given following 14 days of tonsillectomy were tabulated annually from 2008 to 2022. Mann‐Kendall test for monotonic trend examined significant trends in PTH and analgesic use.Results: Mean age at tonsillectomy was 32.8 years (SD = 13.8). 4.1% were diagnosed with PTH in 2008, compared with 6.2% by 2022 (p = 0.0030). In 2008, 0.7% required RTOR to control PTH, compared with 2.4% in 2022 (p < 0.0001). Use of codeine decreased from 6.9% in 2008 to 2.5% in 2022 (p = 0.0022). Use of ibuprofen, acetaminophen, ketorolac, and oxycodone increased from 1.6% to 23.4% (p = 0.0005), 36.1% to 78.6% (p < 0.0001), 1.5% to 11.9% (p < 0.0001), and 20.6% to 63.6% (p < 0.0001), respectively. No change was detected in use of hydrocodone.Conclusion: Post‐tonsillectomy analgesia in adults has changed significantly over the last 15 years. Our study highlights a concurrent increase in PTH which bears more investigation.Level of Evidence: 3 Laryngoscope, 135:1958–1963, 2025
- 1 October 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (2) , 475-482
Navigating the Discrepancy: How Cost of Living (COL) Adjustments Impact Otolaryngology Residents' Salaries
Objective: To compare differences in otolaryngology residents' salaries in different cities and states before and after adjusting for the cost of living.Study Design: Cross‐sectional analysis.Setting: Accreditation Council for Graduate Medical Education (ACGME) otolaryngology residency program websites.Methods: US otolaryngology residency programs were identified via the ACGME database in December 2023. Stipends posted by each residency program were compared to the cost of living (COL) for related states and major cities. A baseline value of 100 was used as the mean COL, values over 100 indicate above‐mean COL. The weighted salary by state and cities for postgraduate year (PGY) 1 to 5 combined was expressed as mean (SD). Comparisons between salaries before and after adjustment for the COL were assessed using t tests.Results: The mean otolaryngology residency stipend across the nation, by city, was $70,572 (n = 1290, range: $58,100‐$93,402; SD = $8370), with a post‐COL adjustment mean stipend of $64,055 (range: $39,193‐$76,674, SD = $10,094, p < .001). Otolaryngology residents in Manhattan, New York State faced a mean decrease from $89,282 to $39,193 (−56%) post‐COL adjustments. Following that were Boston and Los Angeles programs which saw a −$26,402 (−32%) and −$24,761 (−32%) mean decrease after COL adjustments, respectively.Conclusion: Otolaryngology residents in high‐cost areas experience significant salary reductions because of COL adjustments, resulting in financial strain. Residents in such regions endure increased financial pressure compared to those in low‐cost areas, as current salaries fail to align with living expenses.
- 1 October 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (2) , 475-482
Navigating the Discrepancy: How Cost of Living (COL) Adjustments Impact Otolaryngology Residents' Salaries
Objective: To compare differences in otolaryngology residents' salaries in different cities and states before and after adjusting for the cost of living.Study Design: Cross‐sectional analysis.Setting: Accreditation Council for Graduate Medical Education (ACGME) otolaryngology residency program websites.Methods: US otolaryngology residency programs were identified via the ACGME database in December 2023. Stipends posted by each residency program were compared to the cost of living (COL) for related states and major cities. A baseline value of 100 was used as the mean COL, values over 100 indicate above‐mean COL. The weighted salary by state and cities for postgraduate year (PGY) 1 to 5 combined was expressed as mean (SD). Comparisons between salaries before and after adjustment for the COL were assessed using t tests.Results: The mean otolaryngology residency stipend across the nation, by city, was $70,572 (n = 1290, range: $58,100‐$93,402; SD = $8370), with a post‐COL adjustment mean stipend of $64,055 (range: $39,193‐$76,674, SD = $10,094, p < .001). Otolaryngology residents in Manhattan, New York State faced a mean decrease from $89,282 to $39,193 (−56%) post‐COL adjustments. Following that were Boston and Los Angeles programs which saw a −$26,402 (−32%) and −$24,761 (−32%) mean decrease after COL adjustments, respectively.Conclusion: Otolaryngology residents in high‐cost areas experience significant salary reductions because of COL adjustments, resulting in financial strain. Residents in such regions endure increased financial pressure compared to those in low‐cost areas, as current salaries fail to align with living expenses.